ABIONYX Pharma SA (BST:609)

Germany · Delayed Price · Currency is EUR

1.532

+0.072 (4.93%)

At close: Oct 9, 2026

Market Cap	65.20M -45.5%
Revenue (ttm)	4.06M -10.7%
Net Income	-5.55M
EPS	-0.16
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,439
Open	1.478
Previous Close	1.460
Day's Range	1.452 - 1.584
52-Week Range	1.460 - 4.260
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Dec 24, 2026

About ABIONYX Pharma

ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal, metabolic, and ophthalmic diseases in France and the United States. It operates through Research and Development Activities for the Development of Innovative Drugs; and Contract Research Organization (CRO) Activities segments. The company develops CER-001, a recombinant HDL mimetic biopharmaceutical in a Phase III trial for the treatment of lecithin cholesterol acyltransferase (LCAT) deficiency, as well as in a Phase II trial for the treatment of ... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2005

Employees 49

Stock Exchange Stuttgart Stock Exchange

Ticker Symbol 609

Financial Performance

In 2025, ABIONYX Pharma's revenue was 4.06 million, a decrease of -10.72% compared to the previous year's 4.55 million. Losses were -5.55 million, 26.7% more than in 2024.

Financial Statements